23andMe Holding Co. (ME)
USD 0.61
(0.0%)
USD 0.61
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 395.16 Million USD | -58.08% |
| 2022 | 942.59 Million USD | -18.18% |
| 2021 | 1.15 Billion USD | 154.83% |
| 2020 | 452.09 Million USD | 11.73% |
| 2019 | 404.63 Million USD | -41.92% |
| 2018 | 696.68 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 368.04 Million USD | -6.86% |
| 2023 Q2 | 801.23 Million USD | -8.03% |
| 2023 Q1 | 871.19 Million USD | -7.57% |
| 2023 FY | 395.16 Million USD | -58.08% |
| 2023 Q3 | 608.21 Million USD | -24.09% |
| 2023 Q4 | 395.16 Million USD | -35.03% |
| 2022 Q1 | 1.06 Billion USD | -7.8% |
| 2022 Q3 | 1.02 Billion USD | -1.54% |
| 2022 Q4 | 942.59 Million USD | -8.01% |
| 2022 FY | 942.59 Million USD | -18.18% |
| 2022 Q2 | 1.04 Billion USD | -2.02% |
| 2021 Q1 | 947.01 Million USD | 109.47% |
| 2021 FY | 1.15 Billion USD | 154.83% |
| 2021 Q4 | 1.15 Billion USD | -6.05% |
| 2021 Q3 | 1.22 Billion USD | 35.8% |
| 2021 Q2 | 903.04 Million USD | -4.64% |
| 2020 Q4 | 452.09 Million USD | -5.13% |
| 2020 Q2 | - USD | 0.0% |
| 2020 FY | 452.09 Million USD | 11.73% |
| 2020 Q3 | 476.53 Million USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 FY | 404.63 Million USD | -41.92% |
| 2018 FY | 696.68 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aspira Women's Health Inc. | 6.26 Million USD | -6210.556% |
| Biodesix, Inc. | 99.09 Million USD | -298.772% |
| Castle Biosciences, Inc. | 477.81 Million USD | 17.296% |
| IDEXX Laboratories, Inc. | 3.25 Billion USD | 87.878% |
| Illumina, Inc. | 10.11 Billion USD | 96.092% |
| Standard BioTools Inc. | 323.06 Million USD | -22.317% |
| NeoGenomics, Inc. | 1.68 Billion USD | 76.495% |
| Neogen Corporation | 4.58 Billion USD | 91.38% |
| Inotiv, Inc. | 856.53 Million USD | 53.864% |
| Psychemedics Corporation | 13.27 Million USD | -2877.898% |
| RadNet, Inc. | 2.88 Billion USD | 86.311% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -4706.477% |
| T2 Biosystems, Inc. | 34.79 Million USD | -1035.635% |
| Exact Sciences Corporation | 6.47 Billion USD | 93.894% |
| Star Equity Holdings, Inc. | 86.97 Million USD | -354.351% |
| Prenetics Global Limited | 254.17 Million USD | -55.473% |
| iSpecimen Inc. | 15.81 Million USD | -2398.031% |
| OpGen, Inc. | 1.88 Million USD | -20894.127% |
| Neuronetics, Inc. | 115.83 Million USD | -241.158% |
| Precipio, Inc. | 18.1 Million USD | -2083.122% |
| Intelligent Bio Solutions Inc. | 13.77 Million USD | -2767.922% |
| Exagen Inc. | 56.94 Million USD | -593.957% |
| Bionano Genomics, Inc. | 214.4 Million USD | -84.31% |
| CareDx, Inc | 484.61 Million USD | 18.458% |
| Check-Cap Ltd. | 25.01 Million USD | -1479.594% |
| Twist Bioscience Corporation | 776.4 Million USD | 49.103% |
| Guardant Health, Inc. | 1.78 Billion USD | 77.879% |
| BioNexus Gene Lab Corp. | 11.39 Million USD | -3366.44% |
| Natera, Inc. | 1.45 Billion USD | 72.88% |
| Fulgent Genetics, Inc. | 1.27 Billion USD | 68.96% |
| Sera Prognostics, Inc. | 95.44 Million USD | -314.043% |
| OPKO Health, Inc. | 2.01 Billion USD | 80.357% |
| Personalis, Inc. | 225.09 Million USD | -75.553% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -100.181% |
| Applied DNA Sciences, Inc. | 13.65 Million USD | -2794.662% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 67.034% |
| ICON Public Limited Company | 16.98 Billion USD | 97.674% |
| Star Equity Holdings, Inc. | 86.97 Million USD | -354.351% |
| MDxHealth SA | 129.13 Million USD | -206.018% |
| Prenetics Global Limited | 254.17 Million USD | -55.473% |
| DarioHealth Corp. | 96.38 Million USD | -309.971% |
| ENDRA Life Sciences Inc. | 6.75 Million USD | -5750.732% |
| Medpace Holdings, Inc. | 1.65 Billion USD | 76.149% |
| Mainz Biomed B.V. | 15.4 Million USD | -2464.516% |
| Trinity Biotech plc | 59.43 Million USD | -564.873% |
| Sotera Health Company | 3.13 Billion USD | 87.377% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -4706.477% |